PDS Biotechnology Corporation Common Stock (PDSB)
Stock · NASDAQ · Health Care
$1.14as of 10/16/2026
Price chart
Active signals
PDSB Signal Track Record
How signals performed across all stocks →What PDSB's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | -6.9% | 36% | September 2, 2026 |
| Bollinger Band Breakout | 20 | -6.9% | 35% | October 9, 2026 |
| Bollinger Band Breakdown | 20 | +0.6% | 50% | August 11, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -11.1% | 38% | September 18, 2026 |
| Any 20-session window (baseline) | -4.3% | 40% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PDSB
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trial…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 21
- Website
- www.pdsbiotech.com
Fundamentals
- 1-day range
- $1.13$1.26
- Market cap
- $41.78M
- P/E (trailing)
- —
- P/E (forward)
- -3.32
- EPS (trailing)
- $-0.65
- Dividend yield
- —
- Beta
- 1.29
- Avg. volume
- 24.28M
- Dividend pay date
- March 18, 2019
Forecasts
1 analyst ratings
PDS Biotechnology Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- PDSBPDS Biotechnology Corporation Common Stock$1.13▼ 13.08%Market cap $41.78MP/E —$0.1952$1.79
- HYPDHyperion DeFi Inc. Common Stock$2.84▼ 9.84%Market cap $40.47MP/E 7.24$2.34$9.13
- RADXRadiopharm Theranostics Limited American Depositary Shares$1.03▼ 4.63%Market cap $40.11MP/E —$0.0035$0.037
- NSRXNasus Pharma Ltd. Ordinary Shares$3.18▲ 0.47%Market cap $39.70MP/E —$1.98$9.5
- KPTIKaryopharm Therapeutics Inc. Common Stock$0.39▲ 11.11%Market cap $44.19MP/E —$0.31$10.99
- EDSAEdesa Biotech Inc. Common Shares$2.57▼ 3.75%Market cap $44.90MP/E —$0.72$20.32
- APLMApollomics Inc. Class A Ordinary Shares$21.1▲ 0.48%Market cap $37.33MP/E —$10.01$42.12
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PDSB PDS Biotechnology Corporation Common Stock | $41.78M | — | $1.13 | ▼ 13.08% | $0.1952$1.79 |
| HYPD Hyperion DeFi Inc. Common Stock | $40.47M | 7.24 | $2.84 | ▼ 9.84% | $2.34$9.13 |
| RADX Radiopharm Theranostics Limited American Depositary Shares | $40.11M | — | $1.03 | ▼ 4.63% | $0.0035$0.037 |
| NSRX Nasus Pharma Ltd. Ordinary Shares | $39.70M | — | $3.18 | ▲ 0.47% | $1.98$9.5 |
| KPTI Karyopharm Therapeutics Inc. Common Stock | $44.19M | — | $0.39 | ▲ 11.11% | $0.31$10.99 |
| EDSA Edesa Biotech Inc. Common Shares | $44.90M | — | $2.57 | ▼ 3.75% | $0.72$20.32 |
| APLM Apollomics Inc. Class A Ordinary Shares | $37.33M | — | $21.1 | ▲ 0.48% | $10.01$42.12 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’Yahoo · 9/29/2026
- PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA OncologyYahoo · 9/22/2026
- PDS Biotechnology Announces Publication Of Results From Phase 2 Trial Evaluating PDS0101, HPV16-Targeted Immunotherapy, In Combination With Pembrolizumab In JAMA Oncology, Peer Reviewed Journal Of American Medical AssociationBenzinga · 9/22/2026
- PDS Biotechnology (PDSB) Stock Fair Value Moves Lower After Analyst Cuts And Financing ScrutinyYahoo · 9/18/2026
- ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?Yahoo · 9/18/2026
- This Tiny Biotech Is Beating MRNA, IOVA And SLS — Here's How A Billionaire Fueled Its September RallyYahoo · 9/17/2026
- What's going on in today's sessionChartMill · 9/16/2026
- Most active stocks in Wednesday's sessionChartMill · 9/16/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 5.06M
- Total value held
- $3.05M
- Institutional holders
- 39
- Unknown1.63M
- Unknown660.2K
- Unknown554.0K
- Unknown319.1K
- Unknown300.0K
- Unknown220.8K
- Unknown182.0K
- Unknown173.6K
- Unknown133.3K
- Unknown110.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
No recent news for PDSB in the past week
PDSB has not issued any new corporate announcements or earnings releases in the last seven days. The stock is trading near its 52‑week low, with an RSI of 59.5 and a support level at $0.21. Analysts maintain an average target of $4.75, while the 52‑week range spans $0.20 to $1.55. No significant events have impacted the company’s outlook recently.
No recent news for PDSB in the past week. PDSB has not issued any new corporate announcements or earnings releases in the last seven days. The stock is trading near its 52‑week low, with an RSI of 59.5 and a support level at $0.21. Analysts maintain an average target of $4.75, while the 52‑week range spans $0.20 to $1.55. No significant events have impacted the company’s outlook recently.